LOS ANGELES, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endo International plc (“Endo” or the “Company”) (Nasdaq:ENDP) for possible violations of federal securities laws from November 30, 2012 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Endo shares during the Class Period should contact the firm before the October 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at email@example.com.
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Endo made false and/or misleading statements, and/or failed to disclose that: Reformulated Opana was not resistant to crushing; that Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; that Reformulated Opana was contributing to an opioid public health crisis; and that Endo would ultimately remove Reformulated Opana from the market. Upon release of this information, shares of Endo fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.